Allergy drops (liquid sublingual immunotherapy, or SLIT) aren’t covered by most insurance plans in the United States because the liquid formulations have never received FDA approval. Doctors prescribe them “off-label,” using extracts that are only FDA-approved for injection-based allergy shots. Without that formal approval for sublingual use, insurers treat allergy drops as experimental and deny coverage. The result is that patients typically pay entirely out of pocket, even though allergy drops are widely used in Europe and research supports their effectiveness.
The FDA Approval Gap
The core issue is regulatory. The liquid extracts used in allergy drops are the same commercially available extracts approved for subcutaneous injection (allergy shots). When an allergist mixes those extracts into drops you place under your tongue, they’re using an approved product in an unapproved way. That’s considered off-label use, and it’s legal for doctors to prescribe, but it changes how insurers view the treatment.
There’s an important distinction here that confuses many patients: the FDA has approved four sublingual immunotherapy tablets for specific allergens. These are brand-name products (Grastek, Oralair, Ragwitek, and Odactra) that treat grass pollen, ragweed, and dust mite allergies. Because they went through formal FDA trials, they’re more likely to be covered by insurance, though coverage still varies by plan. Liquid allergy drops, which can be customized to target dozens of allergens at once, have never completed that approval process.
Without FDA approval, there are no established dosing guidelines or standardized formulations for liquid drops. This makes insurers uncomfortable. They point to the lack of a formal regulatory green light as justification for denying claims, even when individual studies show the drops work.
No Billing Code Exists for Allergy Drops
Even if an insurer were open to covering allergy drops, the medical billing system creates another barrier. There is no specific billing code (called a CPT code) for sublingual immunotherapy with liquid drops. The existing immunotherapy code only applies to injections, and using it for drops would be incorrect. Allergists can submit claims using a generic “unlisted allergy procedure” code, but most insurers reject claims filed under that code, or require extensive documentation before considering payment.
This creates a catch-22. Insurers rarely create reimbursement pathways for treatments that lack FDA approval, and without a reimbursement pathway, there’s no standardized billing code. The American College of Allergy, Asthma and Immunology advises doctors to check with each patient’s insurer individually, but the practical reality is that coverage is almost always denied.
Off-Label Use and Insurance Policy
Most private insurers and Medicare follow a straightforward rule: off-label uses of a medication need to appear in recognized drug reference guides (called compendia) before they’ll cover them. Liquid sublingual immunotherapy hasn’t made it into these compendia in a way that triggers automatic coverage. Insurers view unlisted off-label uses with caution, partly because of past problems with other medications being used aggressively outside their approved indications.
Cost control also plays a role. Restricting off-label coverage is one of the tools insurers use to limit spending. Even when evidence supports a treatment, the approval-first framework gives insurers a defensible reason to say no.
The Cost Paradox
Here’s what makes the situation frustrating for patients and doctors alike: allergy drops are actually cheaper than allergy shots. A cost-effectiveness analysis comparing the two found that the total charge to an insurer for one year of sublingual therapy was about $670, compared to $1,722 for injection-based therapy. When factoring in how well patients stick with treatment and how effective each method is, the cost per successful outcome was $1,196 for drops versus $2,691 for shots. That’s a savings of roughly $1,500 per patient per year.
Drops also eliminate the need for weekly or biweekly office visits, since patients take them at home. Allergy shots require in-office administration with a 30-minute observation period after each injection, which adds time, travel costs, and copays that don’t show up in the sticker price. A European study found similar results, with sublingual therapy costing less than injections from every perspective, including the insurer’s.
Despite this, the insurance system rewards the more expensive option simply because it has full FDA approval and established billing codes. Patients who choose drops for their convenience and lower total cost end up bearing the full expense themselves.
What You’ll Pay Out of Pocket
The cost of allergy drops varies significantly depending on the clinic, the number of allergens being treated, and your region. Pricing structures differ from practice to practice, with some charging a flat monthly fee and others billing per vial. Because there’s no insurance negotiation setting a standard price, clinics have wide latitude in what they charge. You should ask for a complete cost breakdown before starting treatment, including the initial testing, the drops themselves, and any follow-up appointments.
One way to offset the cost: allergy drops prescribed by a doctor qualify as a medical expense under IRS rules. If your allergist writes a prescription for the drops, you can pay for them using a Health Savings Account (HSA) or Flexible Spending Account (FSA), since prescribed medicines and medical supplies are eligible expenses. This effectively lets you pay with pre-tax dollars, reducing the real cost by whatever your marginal tax rate is. For someone in the 24% tax bracket, that’s a meaningful discount.
FDA-Approved Tablets as an Alternative
If you want sublingual immunotherapy with a better chance of insurance coverage, the four FDA-approved tablets are worth discussing with your allergist. They treat a narrow range of allergens: timothy grass and related northern pasture grasses, ragweed pollen, and house dust mites. You dissolve them under your tongue daily, similar to drops.
The limitation is specificity. If your allergies involve trees, mold, animal dander, or multiple types of pollen, the tablets won’t cover all your triggers. Liquid drops can be customized to include a broad mix of allergens in a single formulation, which is one of their main advantages. For patients with a single dominant allergen that matches an available tablet, though, the FDA-approved option may provide similar relief with insurance helping cover the cost.
Why This Hasn’t Changed
Liquid allergy drops have been used in Europe for decades and are a standard treatment option there. In the U.S., the barrier isn’t evidence of harm or lack of effectiveness. It’s that no pharmaceutical company has taken a liquid sublingual product through the full FDA approval process, which costs hundreds of millions of dollars and takes years. The extracts used in drops are already available as generic products for injection, so there’s little financial incentive for a manufacturer to fund approval trials for a new delivery method of an existing product.
Until that changes, the pattern holds: allergists can legally prescribe liquid drops, many patients benefit from them, they cost less than shots, and insurance won’t pay for them. If you’re considering allergy drops, budgeting for the full out-of-pocket cost and using tax-advantaged accounts are the most practical ways to manage the expense.